Compare Summit Therapeutics Inc (SMMT) vs TTM Technologies Inc. Common Stock (TTMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs TTM Technologies Inc. Common Stock — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while TTM Technologies Inc. Common Stock trades at $121.01 (market cap $12.38B). The key difference: Summit Therapeutics Inc and TTM Technologies Inc. Common Stock are close in size by market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 2,258,598). Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and TTM Technologies Inc. Common Stock for 0 Days on average.
| SMMT | TTMI | |
|---|---|---|
Market Cap | $13.71B | $12.38B |
Volume | 6,173,057 | 2,258,598 |
Sector | Health | Technology |
52-Week High | $26.38 | $221.47 |
52-Week Low | $12.43 | $53.58 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $13.04B | $12.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About TTM Technologies Inc. Common Stock
TTM Technologies manufactures printed circuit boards, radio-frequency components, and electronics assemblies. Its products are used in aerospace, defense, automotive, data center, and communications equipment.
Read more on TTMI →
